Quantum BioPharma Ltd.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Zeeshan Saeed
- Full Time Employees
- 17
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1 Adelaide Street East Toronto ON Canada M5C 2V9
- IPO Date
- Jun 8, 2018
- CIK
- 0001771885
- Website
- quantumbiopharma.com
- Similar Companies
- Business
- Quantum BioPharma Ltd. (QNTM) operates as a biopharmaceutical company focused on researching and developing innovative therapies for neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders; its core pipeline includes the lead compound Lucid-MS, a patented new chemical entity in Phase 2 clinical trials targeting myelin degradation in multiple sclerosis; FSD-PEA, preparing for Phase 2 trials for inflammatory diseases such as mast cell activation syndrome; Lucid-PSYCH for major depressive disorder; and unbuzzd, a dietary supplement for alcohol misuse detoxification licensed to Unbuzzd Wellness Inc., with Quantum retaining 20.10% ownership and 7% royalties on sales up to $250 million. The company conducts operations through two segments, Biopharmaceutical Innovation and Strategic Investments, the latter comprising loans secured by residential and commercial properties; it targets patients with neuropsychiatric and neurodegenerative conditions in global markets, primarily from its headquarters in Toronto, Canada, founded in 1998. Recent developments encompass a name change from FSD Pharma Inc. in August 2024; agreements with a contract development and manufacturing organization via subsidiary Huge Biopharma Australia Pty. Ltd. for Lucid-MS oral formulation production; a joint study with Massachusetts General Hospital validating PET imaging for myelin integrity in multiple sclerosis patients; an IND application package preparation with a global CRO for Lucid-MS submission to the U.S. FDA; strengthened third-quarter 2025 liquidity with closed debt and cryptocurrency gains; and positive early safety signals from MS studies, alongside unbuzzd licensee preparations for a potential IPO capital raise of up to $5 million without equity dilution for Quantum shareholders.
Company News
Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange
Quantum Biopharma Provides Corporate Update
Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial
Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:
Quantum Biopharma (QNTM) Projected to Post Quarterly Earnings on Thursday
Quantum BioPharma Announces Closing of Debt Settlement
Quantum BioPharma Announces Intention to Settle Debt
Quantum BioPharma Announces Intention to Settle Debt
Quantum BioPharma Provides Corporate Update
NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis
Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy
Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.
Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns
Quantum BioPharma Provides Corporate Update
Quantum BioPharma Provides Corporate Update
Quantum BioPharma Momentum Score Surges As Investors Cheer Progress In MS Research
Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital
Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026
Quantum BioPharma Provides Corporate Update